Ovarian stimulation and oocyte cryopreservation in females with cancer.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
pmc-release:
01
09
2024
medline:
9
8
2023
pubmed:
27
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
We reviewed the most recent developments including the safety and effectiveness data and success rates in individualized ovarian stimulation protocols for adult and postpubertal females with cancer. In women with breast cancer, aromatase inhibitor- and tamoxifen-supplemented stimulation protocols increase the margin of safety by limiting estrogen exposure. The outcomes of ovarian stimulation appear similar between cancer and noncancer populations, even with the recently developed random-start protocols, which allow initiation of ovarian stimulation anytime during the menstrual cycle. Based on lower anti-Mullerian hormone levels and primordial follicle density, carriers of BRCA pathogenic variants ( BRCApv ) have decreased ovarian reserve in comparison to women without those variants and may lose larger portion of their ovarian reserve post chemotherapy. Oocyte cryopreservation is also emerging as a suitable fertility preservation approach for selected postpubertal girls as young as 12 years of age. Individualized ovarian stimulation approaches combined with improvements in cryopreservation techniques increased the success and safety margin to preserve fertility with oocyte freezing. Women with BRCApv , on the other hand, may be at disadvantage as they have lower ovarian reserve and may lose larger portion of their ovarian reserve post chemotherapy compared to women who do not carry these variants.
Identifiants
pubmed: 37498110
doi: 10.1097/CCO.0000000000000977
pii: 00001622-202309000-00010
pmc: PMC10528588
mid: NIHMS1914177
doi:
Types de publication
Review
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
412-419Subventions
Organisme : NICHD NIH HHS
ID : R01 HD053112
Pays : United States
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018; 36:1994–2001.
Janát-Amsbury MM, Gupta KM, Kablitz CD, Peterson CM. Drug delivery for in vitro fertilization: rationale, current strategies and challenges. Adv Drug Deliv Rev 2009; 61:871–882.
Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update 2012; 18:73–91.
Sönmezer M, Türkçüoğlu I, Coşkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 2011; 95:2125e9–e11.
Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 2013; 100:1673–1680.
von Wolff M, Capp E, Jauckus J, et al. FertiPROTEKT study group. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. Eur J Obstet Gynecol Reprod Biol 2016; 199:146–149.
Nakasuji T, Kawai K, Ishikawa T, et al. Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer. Reprod Med Biol 2019; 18:167–172.
Ubaldi FM, Capalbo A, Vaiarelli A, et al. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril 2016; 105:1488–1495.
Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 2013; 100:1681–1685.
Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23:4347–4353.
Reddy J, Turan V, Bedoschi G, et al. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet 2014; 31:927–932.
Herzberger EH, Knaneh S, Amir H, et al. Gonadotropin-releasing hormone agonist versus recombinant human chorionic gonadotropin triggering in fertility preservation cycles. Reprod Sci 2021; 28:3390–3396.
De Vos A, Van de Velde H, Joris H, Van Steirteghem A. In-vitro matured metaphase-I oocytes have a lower fertilization rate but similar embryo quality as mature metaphase-II oocytes after intracytoplasmic sperm injection. Hum Reprod 1999; 14:1859–1863.
Oktay K, Buyuk E, Rodriguez-Wallberg KA, Sahin G. In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reprod Biomed Online 2010; 20:634–638.
Domingo J, Guillen V, Ayllon Y, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 2012; 97:930–934.
Pal L, Leykin L, Schifren JL, et al. Malignancy may adversely influence the quality and behavior of oocytes. Hum Reprod 1998; 13:1837–1840.
Klock SC, Zhang JX, Kazer RR. Fertility preservation for female cancer patients: early clinical experience. Fertil Steril 2010; 94:149–155.
Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006; 91:3885–3890.
Quintero RB, Helmer A, Huang JQ, Westphal LM. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril 2010; 93:865–868.
Almog B, Azem F, Gordon D, et al. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. Fertil Steril 2012; 98:957–960.
Quinn MM, Cakmak H, Letourneau JM, et al. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod 2017; 32:568–574.
Turan V, Quinn MM, Dayioglu N, et al. The impact of malignancy on response toovarian stimulation for fertility preservation: a meta-analysis. Fertil Steril 2018; 110:1347–1355.
Volodarsky-Perel A, Cohen Y, Arab S, et al. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response. Hum Reprod 2019; 34:530–538.
Turan V, Oktay K. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging. Hum Reprod Update 2020; 26:43–57.
Govindaraj V, Krishnagiri H, Chakraborty P, et al. Age-related changes in gene expression patterns of immature and aged rat primordial follicles. Syst Biol Reprod Med 2017; 63:37–48.
Titus S, Li F, Stobezki R, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013; 5:172ra21.
Lin W, Titus S, Moy F, et al. Ovarian aging in women with BRCA germline mutations. J Clin Endocrinol Metab 2017; 102:3839–3847.
Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010; 28:240–244.
Turan V, Bedoschi G, Emirdar V, et al. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci 2018; 25:26–32.
Lambertini M, Goldrat O, Ferreira AR, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol 2018; 29:237–243.
Shapira M, Raanani H, Feldman B, et al. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. Fertil Steril 2015; 104:1162–1167.
Derks-Smeets IAP, van Tilborg TC, van A, et al. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. J Assist Reprod Genet 2017; 34:1475–1482.
El Moujahed L, Philis R, Grynberg M, et al. Response to ovarian stimulation for urgent fertility preservation before gonadotoxic treatment in BRCA-pathogenic-variant-positive breast cancer patients. Cancers (Basel) 2023; 15:895.
Kim SW, Kim TH, Han JY, et al. Impact of BRCA mutations and hormone receptor status on reproductive potential in breast cancer patients undergoing fertility preservation. Gynecol Endocrinol 2022; 38:227–230.
Grynberg M, Dagher Hayeck B, Papanikolaou EG, et al. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro. Hum Reprod 2019; 34:374–379.
Rzepka-Gorska I, Tarnowski B, Chudecka-Głaz A, et al. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat 2006; 100:59–63.
Finch A, Valentini A, Greenblatt E, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril 2013; 99:1724–1728.
Giordano S, Garrett-Mayer E, Mittal N, et al. Association of BRCA1 mutations with impaired ovarian reserve: connection between infertility and breast-/ovarian cancer risk. J Adolesc Young Adult Oncol 2016; 5:337–343.
Johnson L, Sammel MD, Domchek S, et al. Antimüllerian hormone levels are lower in BRCA2 mutation carriers. Fertil Steril 2017; 107:1256–1265.e6.
Ben-Aharon I, Levi M, Margel D, et al. Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging? Oncotarget 2018; 9:15931–15941.
Moslehi R, Singh R, Lessner L, Friedman JM. Impact of BRCA mutations on female fertility and offspring sex ratio. Am J Hum Biol 2010; 22:201–205.
Smith KR, Hanson HA, Mineau GP, Buys SS. Effects of BRCA1 and BRCA2 mutations on female fertility. Proc Biol Sci 2012; 279:1389–1395.
van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002; 17:3065–3071.
Turan V, Lambertini M, Lee DY, et al. Association of germline BRCA pathogenic variants with diminished ovarian reserve: a meta-analysis of individual patient-level data. J Clin Oncol 2021; 39:2016–2024.
Oktay KH, Bedoschi G, Goldfarb SB, et al. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. Fertil Steril 2020; 113:1251–1260.
Goldfarb SB, Turan V, Bedoschi B, et al. Presence of BRCA mutations and prechemotherapy serum antimullerian hormone levels predict risk of amenorrhea in women with breast cancer. Cancer Res 2023; 83:5.
Balkenende EME, Dahhan T, Beerendonk CCM, et al. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols. Hum Reprod 2022; 37:1786–1794.
Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008; 26:2630–2635.
Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 2016; 101:1364–1371.
Oktay K, Turan V, Bedoschi G, et al. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 2015; 33:2424–2429.
Lambertini M, Blondeaux E, Bruzzone M, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol 2021; 39:3293–3305.
Hipp HS, Shandley LM, Schirmer DA, et al. Oocyte cryopreservation in adolescent women. J Pediatr Adolesc Gynecol 2019; 32:377–382.
Oktay K, Bedoschi G, Berkowitz K, et al. Fertility preservation in women with turner syndrome: a comprehensive review and practical guidelines. J Pediatr Adolesc Gynecol 2016; 29:409–416.
Lafuente SG, Turan V, Oktay K. Oocyte cryopreservation with in vitro maturation, a feasible option for fertility preservation in adolescents with mosaic turner syndrome. Fertil Steril 2022; 118:e69.
Mamsen LS, Charkiewicz K, Anderson RA, et al. Characterization of follicles in girls and young women with Turner syndrome who underwent ovarian tissue cryopreservation. Fertil Steril 2019; 111:1217–1225.
Cobo A, Coello A, de Los Santos MJ, et al. Number needed to freeze: cumulative live birth rate after fertility preservation in women with endometriosis. Reprod Biomed Online 2021; 42:725–732.
Cobo A, García-Velasco J, Domingo J, et al. Elective and Onco-fertility preservation: factors related to IVF outcomes. Hum Reprod 2018; 33:2222–2231.